Neurocrine Biosciences (NBIX) Free Cash Flow (QoQ) (2010 - 2026)
Neurocrine Biosciences (NBIX) Free Cash Flow (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn |
| 3 | Zoetis | 32.71 Bn | 30.77 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.62 Bn | 23.56 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.18 Bn | 21.03 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.80 Bn | 16.48 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.67 Bn | 12.24 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.52 Bn | 10.37 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -63.05% |
| Dec 31, 2025 | 102.49% |
| Sep 30, 2025 | 74.19% |
| Jun 30, 2025 | 104.81% |
| Mar 31, 2025 | -73.62% |
| Dec 31, 2024 | 27.79% |
| Sep 30, 2024 | 121.38% |
| Jun 30, 2024 | -39.13% |
| Mar 31, 2024 | -2.30% |
| Dec 31, 2023 | -42.47% |
| Sep 30, 2023 | 18.12% |
| Jun 30, 2023 | 242.61% |
| Mar 31, 2023 | -180.13% |
| Dec 31, 2022 | 84.71% |
| Sep 30, 2022 | -39.29% |
| Jun 30, 2022 | 423.33% |
| Mar 31, 2022 | -821.28% |
| Dec 31, 2021 | -109.49% |
| Sep 30, 2021 | -51.04% |
| Jun 30, 2021 | 15.94% |